[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"participants-with-obesity-and-knee-osteoarthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:participants-with-obesity-and-knee-osteoarthritis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100647547","phase-3-a-trial-of-ribupatide-injection-in-participants-with-obesity-and-knee-osteoarthritis-100647547",false,"NCT07709910","A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis","A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis","Inclusion Criteria:\n\n\\-\n\n1、Voluntarily sign the informed consent form, agree to comply with the protocol requirements, and be willing and able to complete the study;\n\n1. 2、Aged ≥18 years on the date of signing the informed consent form, male or female;\n2. 3、BMI ≥28.0 kg\u002Fm² at screening;\n3. 4、Self-reported dietary and exercise control for 3 months or more prior to screening, and body weight change (difference between maximum and minimum body weight within 3 months) ≤5.0 kg in the 3 months prior to screening;\n4. 5、Based on the American College of Rheumatology criteria, the clinical diagnosis is knee osteoarthritis, and the target knee joint X-ray examination shows a K-L grade of 2-3 at screening.\n\nExclusion Criteria:\n\n1. Existence of endocrine diseases that may significantly affect body weight;\n2. Existence of any conditions affecting gastric emptying;\n3. Known history of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic\u002Ftreated gallbladder diseases;\n4. Known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);\n5. Severe infection, major trauma, or major\u002Fmedium surgery within 1 month prior to screening;\n6. History of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening;\n7. History of malignancy in any organ system within 5 years prior to screening;\n8. Existence or suspicion of depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illnesses;\n9. Known or suspected history of alcohol and\u002For drug abuse or addiction;\n10. Symptoms or signs of acute or chronic hepatitis, or any liver disease other than metabolic dysfunction-associated fatty liver disease;\n11. Existence of serious hematologic diseases or any conditions causing hemolysis or red blood cell instability;\n12. Existence of autoimmune diseases requiring systemic glucocorticoid or immunosuppressive therapy during the study period;\n13. Known or suspected allergy to GLP-1 and\u002For GIP receptor agonists or their excipients;\n14. Participation in any drug or medical device clinical trial within 3 months prior to screening;\n15. Blood donation or cumulative blood loss ≥400 mL within 3 months prior to screening, or receipt of blood transfusion within 3 months;\n16. Participants with mental incompetence or language impairments that prevent full understanding or participation in the trial process.","ALL","18 Years",{"count":19,"type":20},382,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.",[26],"Participants With Obesity and Knee Osteoarthritis","NOT_YET_RECRUITING","2026-07-16",{"date":30,"type":31},"2026-07-17","ACTUAL",{"date":33,"type":20},"2026-07",{"date":35,"type":20},"2028-12",{"name":37,"class":38},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY"]